Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an update.
Botanix Pharmaceuticals Limited has announced a change in the interest of its Executive Chair, Vincent Ippolito, who recently exercised 8 million performance rights into fully paid ordinary shares and sold 3.8 million shares on the market. This transaction increases his holding to 15 million shares, supporting tax obligations related to the rights exercise. Mr. Ippolito remains committed to leading the company as it progresses towards becoming a revenue-generating entity.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing dermatology and antimicrobial products. The company aims to transition into a revenue-generating commercial stage pharmaceutical enterprise.
YTD Price Performance: 3.41%
Average Trading Volume: 5,480,381
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$867.2M
Learn more about BOT stock on TipRanks’ Stock Analysis page.
